TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

Inclusion Criteria:

• Histologically or cytologically confirmed metastatic solid tumor, including but not limited to pancreatic adenocarcinoma, breast cancer, melanoma, renal cell carcinoma (RCC), colorectal adenocarcinoma, non-small cell lung cancer, and others approved by the principal investigator
• Persistent, recurrent or progressive disease following at least one prior line of systemic therapy and there is no available therapy likely to improve survival
• Measurable disease with >= 1 target lesion
• White blood cells (WBC) >= 4200/mm^3
• Absolute neutrophil count (ANC) >= 1400/mm^3
• Platelets (PLT) >= 100,000/mm^3
• Lymphocytes >= 700/mm^3
• Hemoglobin >= 10 g/dL
• Total bilirubin =< 1.5 X upper limit of normal (ULN) unless history of Gilbert's syndrome documented prior to first-line treatment of cancer and other liver function tests are within normal limits
• Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.2 x ULN unless on anticoagulation medication with stable dosing for at least one month; in addition, patient must be able to stop taking medication for up to a week in order to have percutaneous biopsies of tumor tissue performed
• Aspartate transaminase (AST) and alanine aminotransferase (ALT) =< 1.5 x ULN (=< 5 x ULN for patients with liver involvement)
• Creatinine =< ULN or a calculated creatinine clearance of >= 45 ml/min if creatinine is greater than the ULN
• Alkaline phosphatase =< 3 x ULN (=< 5 x ULN if liver or bone involvement)
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
• Willing and able to provide informed written consent
• Willing and able to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study); Note: During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing and able to return to the consenting institution for follow-up
• Estimated life expectancy >= 84 days (3 months)
• Willing and able to provide samples for correlative research purposes
• If female of child-bearing potential, have a negative pregnancy test =< 14 days prior to registration
• If fertile male or female of child-bearing potential, agree to consistently use a highly effective method of birth control (including birth control pills, barrier device, or intrauterine device) from the time of consent through 4 months following the last dose of study drug

Exclusion Criteria:

• Is pregnant, breastfeeding, or planning a pregnancy
• Known standard therapy for the patient's disease that is potentially curative
• Treatment with any systemic anticancer treatment or an investigational agent within 4 weeks and any radiation within 2 weeks of registration
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit subject safety or compliance with study requirements
• Active autoimmune disease, defined as any autoimmune condition currently requiring therapy (e.g., systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis)
• History of other invasive malignancy, with the exception of non-melanoma skin cancer and well-excised cervical carcinoma in situ, =< 3 years prior to enrollment unless assessed by the principal investigator as unlikely to compromise subject safety or to interfere with the study's objectives
• Treatment with oral or parenteral corticosteroids dosed greater than 40 mg hydrocortisone daily or its equivalent (e.g., prednisone 10 mg, prednisolone 8 mg, or decadron 3 mg) =< 2 weeks of treatment initiation; or a clinical requirement for ongoing systemic immunosuppressive therapy
• History of central nervous system (CNS) metastases unless previously treated and stable for > 8 weeks prior to study initiation
• Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive
• Hypersensitivity to pegfilgrastim or Escherichia (E.) coli derived proteins